Auto-Injectors Market: By Type (Fillable, Prefilled), by Technology (Automated, Manual), by Usability (Disposable, Reusable), by Application (Anaphylaxis, Rheumatoid Arthritis, Multiple Sclerosis, Others), by Distribution channel (Hospitals, Retail Pharmacies, Online Pharmacies, Others) and Geography  

Auto-Injectors Market size valued 45.4 billion in 2020 and expected to reach USD 109.5 billion by 2027, at a CAGR of 17.6% during the forecast period 2021-2027. Auto-Injector is a medical device that is used to self-inject doses of drugs, typically life-saving drugs. Auto-injector keeps the needle tip covered before injecting and also has a safety mechanism to prevent accidental injection. auto-injector market are gaining importance these days to manage the severe conditions like anaphylaxis, rheumatoid arthritis, multiple sclerosis, and others. Most of the auto-injectors are single-dose and spring-loaded syringes. The site of injection depends upon the drug loaded.  Auto-Injectors are easy to use and intended for self-administration by patients or any other caretaker or personnel at home. auto injector market manufacturers are diversifying the product portfolio by introducing low-cost auto injector products, incorporate advanced features into products, and with new product launches. For instance, Mylan N.V. introduced a generic version of epipen by reducing the price to half of its original product price. The initial pack of two was sold at US$ 600 until December 2016 that will be sold at US$ 300 from January 2017. Bayer AG introduced betaconnect, an electronic auto injector to treat relapsing-remitting multiple sclerosis in 2016. Companies are actively involved in collaborations and taking license agreements for auto-injector technology. In September 2016, Aptar Pharma (AptarGroup, Inc.) collaborated with Becton, Dickinson and Company (BD) to develop an auto injector using prefillable syringes from BD and Aptar Pharma?s two-step auto-injector technology.